| Popis: |
Background Adalimumab significantly reduces the activity of rheumatoid arthritis (RA), but reliable biomarkers of inflammation are still lacking to predict and evaluate the therapeutic response. Serum calprotectin is a mainstay of endogenous activation of the inflammatory response that can be useful as a marker of response to treatment in RA. Objectives To compare the evolution over time of serum calprotectin and C-Reactive Protein (CRP) after initiation of adalimumab. Methods Serum levels of calprotectin, CRP and adalimumab concentration were measured at visits V1 (week 0), V2 (week 4), V3 (week 8), V4 (week 12) and V5 (week 26). Changes in each variable were analyzed at each visit and each variable was compared to each other using a correlation test. Receiving operating characteristic curves were used to estimate the predictive value of response at V5 for calprotectin and CRP at each visit. Results Data from 66 patients were analyzed. Serum calprotectin level decreased from V1 to V5 (3.76 µg/mL [0 – 17.47] to 2.74 µg/mL [0 – 18.83]; p < 0.05). A positive correlation was observed between serum calprotectin and DAS28ESR (Spearman 0.244; p < 0.01), and between CRP and DAS28ESR (Spearman 0.512; p < 0.01) for all visits combined. In contrast to CRP, serum calprotectin and serum calprotectin variation from V1 at each visit, were not predictive of DAS28ESR at V5. Conclusion Serum calprotectin decreases after initiation of adalimumab in RA but was weakly correlated with disease activity at week 26. Serum calprotectin cannot be considered as superior to CRP as predictive marker of therapeutic response in RA after initiation of adalimumab. Disclosure of Interests Guillaume Servant: None declared, Christophe Passot: None declared, Eric Piver: None declared, Oscar Knight: None declared, Valerie Devauchelle-Pensec Grant/research support from: Roche-Chugai, Speakers bureau: MSD, BMS, UCB, Roche, Stephanie Rist: None declared, Aleth Perdriger: None declared, Elisabeth Gervais Speakers bureau: Abbvie, BMS, MSD, Pfzer, Roche, UCB, Novartis, Emmanuelle Dernis: None declared, Benoit Le Goff Speakers bureau: Abbvie, BMS, Janssen, MSD, Pfzer, Sanofi-Genzyme, UCB, Novartis, Laurence Picon: None declared, Philippe Goupille Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Speakers bureau: Abbvie, Biogaran, BMS, Hospira, Janssen, MSD, Pfizer, Sanofi-Genzyme, UCB, Denis Mulleman Speakers bureau: Pfizer, Novartis, Grifols |
